Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Tigulixostat [inn]
2. Wz0pyq6vlu
3. Lc350189
4. Lc-350189
5. 1287766-55-5
6. 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic Acid
7. 1h-pyrazole-4-carboxylic Acid, 1-(3-cyano-1-(1-methylethyl)-1h-indol-5-yl)-
8. Unii-wz0pyq6vlu
9. Schembl1647151
10. Chembl3652780
11. Bdbm121531
12. Cs-0213580
13. Us8729273, 1
| Molecular Weight | 294.31 g/mol |
|---|---|
| Molecular Formula | C16H14N4O2 |
| XLogP3 | 1.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 3 |
| Exact Mass | 294.11167570 g/mol |
| Monoisotopic Mass | 294.11167570 g/mol |
| Topological Polar Surface Area | 83.8 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 486 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
LC350189 (tigulixostat) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase.
Lead Product(s): Tigulixostat
Therapeutic Area: Rheumatology Brand Name: LC350189
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Innovent Biologics
Deal Size: $95.5 million Upfront Cash: $10.0 million
Deal Type: Collaboration December 14, 2022
Lead Product(s) : Tigulixostat
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Innovent Biologics
Deal Size : $95.5 million
Deal Type : Collaboration
Details : LC350189 (tigulixostat) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase.
Brand Name : LC350189
Molecule Type : Small molecule
Upfront Cash : $10.0 million
December 14, 2022
Details:
Results from US Phase 2 clinical trial—primary end point set at a challenging level confirmed the potential of LC350189 (tigulixostat) as a new gout treatment distinguished from pre-existing drugs, while also demonstrating safety similar to that of the placebo group.
Lead Product(s): Tigulixostat
Therapeutic Area: Rheumatology Brand Name: LC350189
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Lead Product(s) : Tigulixostat
Therapeutic Area : Rheumatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LG Chem Enters Final Stage of Clinical Development for New Gout Drug
Details : Results from US Phase 2 clinical trial—primary end point set at a challenging level confirmed the potential of LC350189 (tigulixostat) as a new gout treatment distinguished from pre-existing drugs, while also demonstrating safety similar to that of the...
Brand Name : LC350189
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
